Risankizumab Efficacy in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Remission: A Case Report on Rheumatologic and Dermatologic Disease Manifestations with Literature Review

Table 1

Health-related quality of life measured through the SF-36 questionnaire and in weeks after therapy initiation.

	Week 0 (%)	Week 16 (%)	Week 24 (%)	Week 52 (%)
Physical functioning	35	70	80	90
Role limitations due to
Physical health	50	50	65	45
Emotional problems	66.7	66.7	100	100
Energy/fatigue	45	60	70	75
Emotional well-being	76	64	58	68
Social functioning	37.5	50	50	75
Pain	35	45	55	77.5
General health	20	25	50	65
Health change	25	75	75	75